

*F1*  
36. (Amended) The expression vector as set forth in claim 35, in which the mRNA-destabilizing sequence is an mRNA-destabilizing sequence of a c-fos gene.

*F2*  
38. (Amended) Cells into which the expression vector as set forth in claim 35 has been transferred and selected with the drug.

39. (Amended) A process for producing cells expressing a gene product encoded by the expression vector as set forth in claim 35, comprising:

- (a) transferring the expression vector into cells,
- (b) selecting cells which express the drug resistance gene from the transferred expression vector, and
- (c) expressing the gene product encoded by the expression vector in the selected cells.

Kindly enter the following new claims.

*F3*  
40. (New) A process for expressing a gene product encoded by the expression vector as set forth in claim 35, comprising:

- (a) transferring the expression vector into cells having gag and pol genes of a retrovirus,
- (b) selecting prepackaging cells which express the drug resistance gene from the transferred expression vector, and
- (c) expressing the gene product encoded by the expression vector in the selected prepackaging cells.

41. (New) The expression vector as set forth in claim 34, in which the mRNA-destabilizing sequence is an mRNA-destabilizing sequence of a c-fos gene.

42. (New) The expression vector as set forth in claim 34, in which the drug-resistance gene is selected from the group consisting of a neomycin resistance gene, a puromycin resistance gene and a hygromycin resistance gene.

43. (New) Cells into which the expression vector as set forth in claim 34 has been transferred and selected with the drug.

44. (New) A process for producing cells expressing a gene product encoded by the expression vector as set forth in claim 34, comprising:

- (a) transferring the expression vector into cells,  
(b) selecting cells which express the drug resistance gene from the transferred expression vector, and  
(c) expressing the gene product encoded by the expression vector in the selected cells.

45. (New) A process for expressing a gene product encoded by the expression vector as set forth in claim 34, comprising:

- (a) transferring the expression vector into cells having gag and pol genes of a retrovirus,  
(b) selecting prepackaging cells which express the drug resistance gene from the transferred expression vector, and  
(c) expressing the gene product encoded by the expression vector in the selected prepackaging cells.